



Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019

May 2, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2019-- [Dicerna™Pharmaceuticals, Inc.](#) (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2019 financial results after market close on Thursday, May 9, 2019.

Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and will be available on the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website.

The call can also be accessed by dialing (855) 453-3834 or +1 (484) 756-4306 (international) and referencing conference ID 4749943 prior to the start of the call. After the conference call, a replay will be available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and refer to conference ID 4749943.

About Dicerna™Pharmaceuticals, Inc.

Dicerna™Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between these genes and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190502005881/en/>

Source: Dicerna™Pharmaceuticals, Inc.

Investors:

Stern Investor Relations, Inc.
Kendra Packard, 212-362-1200
Kendra.packard@sternir.com

Media:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com